Publication:
Reply to: "The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD".

dc.contributor.authorAmpuero, Javier
dc.contributor.authorGallego-Duran, Rocio
dc.contributor.authorRomero-Gomez, Manuel
dc.date.accessioned2023-02-09T10:38:40Z
dc.date.available2023-02-09T10:38:40Z
dc.date.issued2021
dc.description.abstractMao et al. suggest the modification of several parameters employed in the paper for the diagnosis of the dysmetabolic-related outcomes. First, these authors propose using glucose intolerance tests instead of a diagnosis of type 2 diabetes mellitus as an outcome measure . We fully agree with the correspondents about the usefulness of the early detection of glucose intolerance due to the capacity to prevent further events in patients at risk of progressing to diabetes mellitus . However, these tests, such as oral glucose tolerance test , are not suitable for a wide screening of patients because they are time -consuming (2 hours duration) and not cost -effective in this scenario.3 Further, these tests are typically carried out in dedicated units, such as Endocrinology units
dc.description.versionSi
dc.identifier.citationAmpuero J, Gallego-Durán R, Romero-Gómez M. Reply to: "The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD". J Hepatol. 2021 Apr;74(4):971-972.
dc.identifier.doi10.1016/j.jhep.2020.12.020
dc.identifier.essn1600-0641
dc.identifier.pmid33359898
dc.identifier.unpaywallURLhttp://www.journal-of-hepatology.eu/article/S0168827820338952/pdf
dc.identifier.urihttp://hdl.handle.net/10668/16846
dc.issue.number4
dc.journal.titleJournal of hepatology
dc.journal.titleabbreviationJ Hepatol
dc.language.isoen
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number971-972
dc.publisherElsevier BV
dc.pubmedtypeLetter
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.pubmedtypeComment
dc.relation.publisherversionhttps://linkinghub.elsevier.com/retrieve/pii/S0168-8278(20)33895-2
dc.rights.accessRightsRestricted Access
dc.subjectFibrosis
dc.subjectHumans
dc.subjectLiver Cirrhosis
dc.subjectNon-alcoholic Fatty Liver Disease
dc.subject.decsIntolerancia a la glucosa
dc.subject.decsDiabetes Mellitus
dc.subject.decsPrueba de Tolerancia a la glucosa
dc.subject.decsMonoaminooxidasa
dc.subject.decsEndocrinología
dc.subject.meshGlucose Intolerance
dc.subject.meshDiabetes Mellitus, Type 2
dc.subject.meshGlucose Tolerance Test
dc.subject.meshEarly Diagnosis
dc.subject.meshOutcome Assessment, Health Care
dc.titleReply to: "The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD".
dc.typeletter to the editor
dc.type.hasVersionVoR
dc.volume.number74
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
RISalud_Accesorestringido.pdf
Size:
93.39 KB
Format:
Adobe Portable Document Format